Cytovale secures USD 84M to expand IntelliSep across US hospitals

Cytovale has secured an $84 million Series C funding round to expand its revolutionary rapid sepsis diagnosis test IntelliSep across U.S. hospitals. This significant financial boost, spearheaded by Norwest Venture Partners and Zack Scott as a general partner, will address the critical issue of delayed sepsis diagnosis—a problem contributing to a staggering annual cost of $62 billion.

The funding round also saw participation from Sands Capital, and GHIC, along with a mix of new and existing investors. TD Cowen played a pivotal role as the financial advisor during the fundraising process.

IntelliSep stands out in the medical field by delivering results within an impressive 10-minute timeframe. The test operates by applying pressure to white blood cells and utilizing machine learning technology to analyze their responses. The outcome is a score that indicates the likelihood of a patient having or developing sepsis within a three-day window. This score is crucial for healthcare providers to determine the necessary treatment steps promptly.

The implementation of IntelliSep has already begun in select hospitals, including Our Lady of the Lake Regional Medical Center, which was the first to adopt the technology. The introduction of IntelliSep has resulted in a significant reduction in all-hands-on-deck alerts, streamlining the hospital’s response to potential sepsis cases.

Chris Thomas from Franciscan Missionaries of Our Lady Health System highlighted IntelliSep’s impact, noting that it enables them to concentrate resources on the most critical patients. By accurately diagnosing sepsis, IntelliSep helps avoid both overdiagnosis and underdiagnosis—issues that can lead to unnecessary medical costs and adverse health outcomes.

Cytovale’s mission aligns with improving human health through innovative diagnostic solutions like IntelliSep. Meanwhile, Norwest Venture Partners continues to manage an extensive capital portfolio exceeding $12.5 billion, supporting ventures that show promise in enhancing healthcare delivery and outcomes. Investing.com